Evidence map›Paper›PMID 36923914›Full record

ArticleACS medicinal chemistry letters2023

Continuous-Flow Technology for Chemical Rearrangements: A Powerful Tool to Generate Pharmaceutically Relevant Compounds.

Antonella Ilenia Alfano, Sveva Pelliccia, Giacomo Rossino, Orazio Chianese, Vincenzo Summa, Simona Collina, Margherita Brindisi

Full text read
In one paragraph

Article in ACS medicinal chemistry letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Antonella Ilenia AlfanoDepartment of Pharmacy (DoE 2023-2027), University of Naples Federico II, via D. Montesano 49, 80131, Naples, Italy.
Sveva PellicciaDepartment of Pharmacy (DoE 2023-2027), University of Naples Federico II, via D. Montesano 49, 80131, Naples, Italy.ORCID https://orcid.org/0000-0002-5526-5554
Giacomo RossinoDepartment of Drug Sciences, University of Pavia, Via Taramelli 12, 27100 Pavia, Italy.
Orazio ChianeseGenetic S.p.A., Via Canfora, 64, 84084 Fisciano (Salerno), Italy.
Vincenzo SummaDepartment of Pharmacy (DoE 2023-2027), University of Naples Federico II, via D. Montesano 49, 80131, Naples, Italy.ORCID https://orcid.org/0000-0002-6288-2681
Simona CollinaDepartment of Drug Sciences, University of Pavia, Via Taramelli 12, 27100 Pavia, Italy.ORCID https://orcid.org/0000-0002-2954-7558
Margherita BrindisiDepartment of Pharmacy (DoE 2023-2027), University of Naples Federico II, via D. Montesano 49, 80131, Naples, Italy.ORCID https://orcid.org/0000-0001-9119-3773

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The efficacy, safety, and scale-up of several chemical rearrangements remain unsolved problems due to the associated handling of hazardous, toxic, and pollutant chemicals and high-risk intermediates. For many years batch processes have been considered the only possibility to drive these reactions, but continuous-flow technology has emerged, for both academic laboratories and pharmaceutical companies, as a powerful tool for easy, controlled, and safer chemistry protocols, helping to minimize the formation of side products and increase reaction yields. This Technology Note summarizes recently reported chemical rearrangements using continuous-flow approaches, with a focus on Curtius, Hofmann, and Schmidt reactions. Flow protocols, general advantages and safety aspects, and reaction scope for the generation of both privileged scaffolds and active pharmaceutical ingredients will be showcased.

Identifiers

PMID36923914
PMCPMC10009796

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read98
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.